PPARG c.1347C>T polymorphism is associated with cancer susceptibility: from a case-control study to a meta-analysis
- PMID: 29254243
- PMCID: PMC5731953
- DOI: 10.18632/oncotarget.20925
PPARG c.1347C>T polymorphism is associated with cancer susceptibility: from a case-control study to a meta-analysis
Abstract
Recently, several studies suggested that PPARG c.1347C>T polymorphism was correlated with cancer risk. However, past results remained controversial. In this study, we performed a case-control study on the relationship of PPARG c.1347C>T polymorphism with risk of non-small cell lung cancer (NSCLC) and subsequently carried out a meta-analysis to further assess the association between PPARG c.1347C>T and overall cancer. In our case-control study, after adjusting by age, sex, body mass index (BMI), smoking and drinking, a tendency to increased NSCLC risk was noted (CT/TT vs. CC: adjusted OR, 1.21; 95% CI, 0.97-1.51; P = 0.097). In the meta-analysis, we found a significant association between PPARG c.1347C>T polymorphism and overall cancer risk (T vs. C: OR, 1.13; 95% CI, 1.03-1.23; P = 0.006; TT vs. CC: OR, 1.29; 95% CI, 1.07-1.56; P = 0.008, CT/TT vs. CC: OR, 1.11; 95% CI, 1.02-1.21; P = 0.014 and TT vs.
Ct/cc: OR, 1.26; 95% CI, 1.04-1.52; P = 0.016). In a subgroup analysis by ethnicity, evidence of significant association between PPARG c.1347C>T polymorphism and cancer risk was found among Asians and mixed populations. In a subgroup analysis by cancer type, PPARG c.1347C>T polymorphism was associated with risk of esophageal cancer and glioblastoma. In addition, in a subgroup analysis by origin of cancer cell, evidence of significant association between PPARG c.1347C>T polymorphism and cancer risk was also found among epithelial tumor. In conclusion, the findings indicate PPARG c.1347C>T polymorphism may increase the susceptibility of cancer.
Keywords: PPARG; non-small cell lung cancer; polymorphism; risk.
Conflict of interest statement
CONFLICTS OF INTEREST The authors have no potential financial conflicts of interest.
Figures




References
-
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. - PubMed
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
-
- Medina-Gomez G, Gray S, Vidal-Puig A. Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma), PPARgammacoactivator-1 (PGC1) Public Health Nutr. 2007;10:1132–1137. - PubMed
-
- Gandhi GR, Stalin A, Balakrishna K, Ignacimuthu S, Paulraj MG, Vishal R. Insulin sensitization via partial agonism of PPARgamma and glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway by embelin in type 2 diabetic rats. Biochim Biophys Acta. 2013:2243–2255. 1830. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous